Skip to main content
. 2020 Aug 20;5(16):e138034. doi: 10.1172/jci.insight.138034

Figure 2. Effects of FKGK18-withdrawal regimen on T1D incidence and glucose tolerance.

Figure 2

Female NOD mice were administered FKGK18 (20 mg/kg, 3 × weekly, n = 18) or vehicle (PBS-T, n = 17) starting at 10 days of age and until 14 weeks of age. (A) T1D incidence. Blood glucose was monitored weekly for up to 30 weeks, and 2 consecutive readings of ≥ 275 mg/dL were recorded as onset of T1D. (B and D) Glucose tolerance test (GTT). Assessed at 14 (B) and 25 (D) weeks of age (data are presented as mean ± SEM), as described in Figure 1. (C and E) Corresponding AUC. N values for PBS-T & FKGK18: 8 and 8 (B and C); , 8 and 6 (D and E), respectively. Statistical analyses: (A) Mantel-Cox test; (C and E) Student’s t test.